Skip to content

Journal · Pharmaceutical medicine · Updated 21 November 2026

Pharmaceutical Medicine

Read Pharmaceutical Medicine articles on DeepDyve. No university library needed.

Pharmaceutical Medicine covers how medicines are developed, regulated and monitored, from evidence generation and clinical trial recruitment to medication safety and drug policy on antimicrobial resistance. Springer Nature publishes it. It was previously published as International Journal of Pharmaceutical Medicine. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Pharmaceutical Medicine
Journal cover

Pharmaceutical Medicine at a glance

Full title
Pharmaceutical Medicine
Former title
International Journal of Pharmaceutical Medicine
Abbreviation (NLM)
Pharmaceut Med
Publisher
Springer Nature
Print ISSN
1178-2595
Online ISSN (eISSN)
1179-1993
Current title since
2008
Access model
Hybrid (54% free to read in 2026)

Ways to access Pharmaceutical Medicine

54% of the articles Pharmaceutical Medicine published from January 1 to November 20, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 54% of Pharmaceutical Medicine articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Pharmaceutical Medicine. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Pharmaceutical Medicine articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Pharmaceutical Medicine’s 2025 Journal Impact Factor is 4.7, and its 5-year Impact Factor is 4.3.

4.7

Journal Impact Factor (2025)

4.3

5-year Impact Factor (2025)

10 days

Median time to first decision

Source: journal metrics on the Pharmaceutical Medicine homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Pharmaceutical Medicine research worth reading

Published January to September 2026. Summaries describe what the authors report.

  1. Open accessReal-world evidence · Medical affairs

    Shaping the Future of Evidence Generation: Real-World Data to Drive Healthcare Transformation and Patient-Centered Decisions

    The authors describe the evidence generation framework AstraZeneca Spain’s Medical Affairs team put in place, combining real-world data, outcomes research and patient experience studies with a data visualization tool called ATLAS and outcome-based agreements with payers.

    Medina et al. · Pharmaceutical Medicine, published online January 28, 2026 · DOI 10.1007/s40290-025-00599-2

  2. Open accessEvidence planning · Medical affairs

    Integrated Evidence Generation Planning: Why Medical Affairs is a Critical Partner

    The authors present integrated evidence generation plans as a collaborative process that brings evidence activities together across functions and regions, and argue that Medical Affairs is well placed to lead them in close partnership with Market Access and Clinical Development.

    Fujii et al. · Pharmaceutical Medicine, published online August 10, 2026 · DOI 10.1007/s40290-026-00620-2

  3. LitStreamAntimicrobial resistance · Drug regulation

    The Combat Against Antimicrobial Resistance: An Overview of EU Recent Health Policies and Drug Regulations Promoting the Development of New Antimicrobials

    Reviewing EU policies and drug regulations meant to spur new antimicrobials, the authors report that the European Medicines Agency authorized only 14 new antibiotics between 2015 and 2024, and describe incentives, regulatory tools and growing interest in bacteriophage therapy.

    Daher et al. · Pharmaceutical Medicine, published online February 26, 2026 · DOI 10.1007/s40290-026-00601-5

  4. LitStreamClinical trials · Artificial intelligence

    From Invisible to Enrolled: How Artificial Intelligence Is Reshaping Clinical Trial Recruitment

    The author reviews AI and large language models in clinical trial recruitment, concluding that they can help find eligible patients in health records but cannot remove the barriers to enrollment, and that evidence of gains in enrollment remains limited.

    Ahn · Pharmaceutical Medicine, published online September 6, 2026 · DOI 10.1007/s40290-026-00635-9

  5. LitStreamMedication safety · Health policy

    Medication Safety in India and Southeast Asia: A SWOT Analysis of Policies and Practices

    Using a SWOT analysis of medication safety policies in India and Southeast Asia, the authors report shared gaps such as missing centralized drug registries and under-reporting of adverse events, and propose priorities including QR codes for high-risk medicines and blame-free reporting.

    Sharma et al. · Pharmaceutical Medicine, published online August 18, 2026 · DOI 10.1007/s40290-026-00626-w

See every Pharmaceutical Medicine article on DeepDyve

Questions about Pharmaceutical Medicine

How can I read Pharmaceutical Medicine articles without a subscription?

54% of Pharmaceutical Medicine articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Pharmaceutical Medicine articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Pharmaceutical Medicine?

Pharmaceutical Medicine’s NLM (PubMed) abbreviation is Pharmaceut Med.

What is the ISSN of Pharmaceutical Medicine?

The print ISSN is 1178-2595 and the online ISSN is 1179-1993.

What is the impact factor of Pharmaceutical Medicine?

Pharmaceutical Medicine’s Journal Impact Factor is 4.7 (2025), and its 5-year Impact Factor is 4.3, according to Springer Nature’s published metrics.

Is Pharmaceutical Medicine open access?

Pharmaceutical Medicine is a hybrid journal: authors can choose to publish open access or under the subscription model. From January 1 to November 20, 2026, 25 of 46 Pharmaceutical Medicine articles (54%) carry a Creative Commons license, per Crossref.

Pharmaceutical Medicine articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Pharmaceutical Medicine today

One month free, then less than $2 a day. Pharmaceutical Medicine, plus millions of articles from thousands of journals.

Start free month

Like this: